20 August 2015 : Clinical Research
Levosimendan Improves Clinical Outcomes of Refractory Heart Failure in Elderly Chinese Patients
Dengqing ZhangABDE, Yuanqing YaoCE, Jun QianDE, Jing HuangADOI: 10.12659/MSM.893580
Med Sci Monit 2015; 21:2439-2445
Abstract
BACKGROUND: Levosimendan has been extensively used to treat heart failure (HF) for nearly 10 years, but data on levosimendan used in elderly patients with refractory HF remains limited. This study aimed to investigate the effects of levosimendan on elderly patients with intractable HF.
MATERIAL AND METHODS: A total of 268 patients with HF (over 70 years, New York Heart Association [NYHA] classification III–IV, LVEF ≤40%, plasma NT-proBNP ≥1000 pg/mL) received conventional anti-HF therapies for 2 weeks. Such therapies include the limiting of salt intake, increasing myocardial contractility (without levosimendan), inducing urine, antagonizing aldosterone, antagonizing myocardial remodeling, and, if necessary, using antibiotics. Our study included 42 patients without symptoms whose improvement was re-evaluated and presented in NYHA class III–IV, LVEF ≤40%, plasma NT-proBNP ≥1000.0 pg/mL, and serum creatinine <110.0 µmol/L. These patients were divided into an experimental groups (n=21, treated with levosimendan) and a control group (n=21, continuously given regular treatment as before). After 1 week, 42 patients were assessed for changes in NYHA classification, LVEF, and NT-proBNP.
RESULTS: No severe complications related to levosimendan were noted. Compared with the control group, NYHA classification (I–II: 1 versus 21, III–IV: 20 versus 0, P<0.05) and LVEF (30.62±6.19% versus 45.83±5.06%, P<0.05) were increased, and plasma NT-proBNP was reduced (458.35±193.16 pg/mL versus 2921.52±1395.97 pg/mL, P<0.05) in the experimental group.
CONCLUSIONS: Our study showed levosimendan significantly and safely improved clinical outcomes of refractory heart failure in elderly patients.
Keywords: Anti-Arrhythmia Agents - therapeutic use, Aged, 80 and over, Asian Continental Ancestry Group, China, Creatinine - blood, Heart Failure - physiopathology, Hydrazones - therapeutic use, Natriuretic Peptide, Brain - blood, Peptide Fragments - blood, Prospective Studies, Pyridazines - therapeutic use, Stroke Volume - drug effects
Most Viewed Current Articles
13 Apr 2020 : Original article
Outcome of 24 Weeks of Combined Schroth and Pilates Exercises on Cobb Angle, Angle of Trunk Rotation, Chest...DOI :10.12659/MSMBR.920449
Med Sci Monit Basic Res 2020; 26:e920449
11 May 2020 : Original article
Analysis of Psychological and Sleep Status and Exercise Rehabilitation of Front-Line Clinical Staff in the ...DOI :10.12659/MSMBR.924085
Med Sci Monit Basic Res 2020; 26:e924085
05 Jan 2021 : Review article
A Southeast Asian Perspective on the COVID-19 Pandemic: Hemoglobin E (HbE)-Trait Confers Resistance Against...DOI :10.12659/MSMBR.929207
Med Sci Monit Basic Res 2021; 27:e929207
10 Aug 2020 : Clinical Research
Effects of Cognitive Task Training on Dynamic Balance and Gait of Patients with Stroke: A Preliminary Rando...DOI :10.12659/MSMBR.925264
Med Sci Monit Basic Res 2020; 26:e925264